Article Versions Notes

Alhalmi A, Amin S, Khan Z, Beg S, Al kamaly O, Saleh A, Kohli K. Nanostructured Lipid Carrier-Based Codelivery of Raloxifene and Naringin: Formulation, Optimization, In Vitro, Ex Vivo, In Vivo Assessment, and Acute Toxicity Studies. Pharmaceutics. 2022; 14(9):1771. https://doi.org/10.3390/pharmaceutics14091771

Alhalmi, Abdulsalam, Saima Amin, Zafar Khan, Sarwar Beg, Omkulthom Al kamaly, Asmaa Saleh, and Kanchan Kohli. 2022. "Nanostructured Lipid Carrier-Based Codelivery of Raloxifene and Naringin: Formulation, Optimization, In Vitro, Ex Vivo, In Vivo Assessment, and Acute Toxicity Studies" Pharmaceutics 14, no. 9: 1771. https://doi.org/10.3390/pharmaceutics14091771

Alhalmi, A., Amin, S., Khan, Z., Beg, S., Al kamaly, O., Saleh, A., & Kohli, K. (2022). Nanostructured Lipid Carrier-Based Codelivery of Raloxifene and Naringin: Formulation, Optimization, In Vitro, Ex Vivo, In Vivo Assessment, and Acute Toxicity Studies. Pharmaceutics, 14(9), 1771. https://doi.org/10.3390/pharmaceutics14091771